GlaxoSmithKline plc (LON:GSK) had its price objective decreased by analysts at J P Morgan Chase & Co from GBX 1,750 ($22.60) to GBX 1,570 ($20.28) in a research report issued on Wednesday. The brokerage currently has a “neutral” rating on the stock. J P Morgan Chase & Co’s price target indicates a potential upside of 6.05% from the stock’s previous close.
A number of other analysts have also issued reports on the stock. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.54) target price on shares of GlaxoSmithKline plc and gave the company a “buy” rating in a research note on Wednesday, July 26th. Barclays PLC reissued an “equal weight” rating and set a GBX 1,550 ($20.02) target price on shares of GlaxoSmithKline plc in a research note on Monday, July 3rd. Jefferies Group LLC reissued a “buy” rating and set a GBX 1,900 ($24.54) target price on shares of GlaxoSmithKline plc in a research note on Thursday, July 13th. Berenberg Bank raised shares of GlaxoSmithKline plc from a “hold” rating to a “buy” rating and boosted their target price for the company from GBX 1,850 ($23.89) to GBX 1,885 ($24.34) in a research note on Friday, May 26th. Finally, Deutsche Bank AG reissued a “hold” rating and set a GBX 1,720 ($22.21) target price on shares of GlaxoSmithKline plc in a research note on Tuesday, July 25th. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have assigned a buy rating to the company. GlaxoSmithKline plc presently has a consensus rating of “Hold” and an average price target of GBX 1,705.90 ($22.03).
GlaxoSmithKline plc (LON:GSK) opened at 1463.00 on Wednesday. GlaxoSmithKline plc has a one year low of GBX 1,446.50 and a one year high of GBX 1,745.56. The firm has a 50-day moving average of GBX 1,509.65 and a 200 day moving average of GBX 1,611.61. The company’s market capitalization is GBX 71.51 billion.
ILLEGAL ACTIVITY WARNING: “GlaxoSmithKline plc (GSK) PT Lowered to GBX 1,570” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/09/15/glaxosmithkline-plc-gsk-pt-lowered-to-gbx-1570.html.
In related news, insider Manvinder Singh Banga acquired 2,267 shares of the business’s stock in a transaction dated Wednesday, July 26th. The shares were purchased at an average price of GBX 1,599 ($20.65) per share, for a total transaction of £36,249.33 ($46,815.61). Also, insider Patrick Vallance acquired 861 shares of the business’s stock in a transaction dated Friday, July 14th. The shares were bought at an average price of GBX 1,618 ($20.90) per share, for a total transaction of £13,930.98 ($17,991.71). In the last 90 days, insiders have bought 3,152 shares of company stock worth $5,055,023.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.